Invesco
ALDX icon

Invesco’s Aldeyra Therapeutics ALDX Stock Holding History

Invesco’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Sell
159,540
-10,158
-6% -$17.5K ﹤0.01% 3398
2026
Q1 		$287K Buy
169,698
+6,611
+4% +$29K ﹤0.01% 3360
2025
Q4 		$845K Buy
163,087
+29,382
+22% +$151K ﹤0.01% 2980
2025
Q3 		$698K Buy
133,705
+11,139
+9% +$58.1K ﹤0.01% 3093
2025
Q2 		$469K Sell
122,566
-378,571
-76% -$979K ﹤0.01% 3184
2025
Q1 		$2.88M Buy
501,137
+471,231
+1,576% +$2.79M ﹤0.01% 2405
2024
Q4 		$149K Sell
29,906
-626,604
-95% -$3.22M ﹤0.01% 3566
2024
Q3 		$3.54M Buy
656,510
+626,646
+2,098% +$2.98M ﹤0.01% 2402
2024
Q2 		$98.8K Sell
29,864
-1,962
-6% -$7.68K ﹤0.01% 3754
2024
Q1 		$104K Buy
31,826
+61
+0.2% +$201 ﹤0.01% 3734
2023
Q4 		$111K Sell
31,765
-16,313
-34% -$50.3K ﹤0.01% 3671
2023
Q3 		$321K Sell
48,078
-467,263
-91% -$3.47M ﹤0.01% 3425
2023
Q2 		$4.32M Buy
515,341
+232,635
+82% +$2.29M ﹤0.01% 2317
2023
Q1 		$2.81M Buy
282,706
+35,655
+14% +$252K ﹤0.01% 2497
2022
Q4 		$1.72M Buy
247,051
+19,215
+8% +$110K ﹤0.01% 2705
2022
Q3 		$1.22M Buy
+227,836
New +$1.37M ﹤0.01% 2851
2022
Q2 		– Sell
-16,375
Closed -$73K – 4034
2022
Q1 		$73K Sell
16,375
-378
-2% -$1.51K ﹤0.01% 3894
2021
Q4 		$67K Sell
16,753
-6,605
-28% -$50.4K ﹤0.01% 3948
2021
Q3 		$205K Buy
23,358
+5,807
+33% +$53.3K ﹤0.01% 3792
2021
Q2 		$199K Buy
+17,551
New +$211K ﹤0.01% 3790
2020
Q4 		– Sell
-624,738
Closed -$4.63M – 3766
2020
Q3 		$4.63M Buy
+624,738
New +$4.04M ﹤0.01% 2047

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Invesco's ALDX Position: Q2 2026 in Review

Invesco reduced its Aldeyra Therapeutics (ALDX) stake by 6% in Q2 2026, selling an estimated $17.5K and leaving 159,540 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #3398.

Invesco first reported a position in ALDX in Q3 2020 and has held it in 21 quarters since. The position peaked at $4.63M in Q3 2020. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Invesco held 159,540 shares of Aldeyra Therapeutics worth $340K as of Q2 2026.
  • Invesco sold 10,158 Aldeyra Therapeutics shares in Q2 2026, an estimated $17.5K.
  • Aldeyra Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3398 holding.
  • Invesco first reported a position in Aldeyra Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Invesco's Aldeyra Therapeutics position peaked at $4.63M in Q3 2020.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.